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Prognostic models that predict the clinical course of a breast
cancer patient and provide a rationale for her treatment are of
central importance in oncology. Despite many projects and
hundreds of papers in the last 2 decades only the nodal status is
equivocally considered by all study groups as a strong factor in
patients without metastases (M0). Even the prognostic value of
‘standard factors’ such as tumour size, tumour grade, histologic
type, oestrogen (ER) and progesterone receptor (PR) status,
menopausal status and age is still controversial. During the last
few years many new factors (clinicopathological, biological,
molecular) have been investigated resulting in more than 100
proposed factors, most of them controversial. In addition to labo-
ratory and clinically related problems in obtaining objective and
reproducible measurements of a new factor, heterogeneity in
patient populations and treatment or limitations of follow-up, a
substantial part of this controversy concerns statistical aspects
such as inadequate sample sizes, inadequate use of statistical
methods and difficulties in comparing multivariable models with
different factors or different categorizations of the factors (Simon
and Altman, 1994).
In cancer clinical trials, where survival or recurrence-free
survival (RFS) time is often the primary outcome variable, the
statistical analysis is usually performed with the Cox proportional
hazards model (Cox, 1972) where the effects of several prognostic
factors on the risk of death are modelled simultaneously. The ques-
tion arises as to how the factors should be included in the model,
i.e. which form of relationship is to be assumed between a factor
and the outcome variable. For factors like menopausal status (pre,
peri, post) or tumour grade (I, II, III) with only two or a few levels,
no major modelling difficulties arise. Binary variables can be used
to indicate the membership of the patient to the corresponding
level and the relative risks between the levels of the factor may be
estimated in standard fashion.
Problems arise for continuous prognostic factors with many
different values, e.g. age in years or tumour size in mm. Usually,
such factors are included in the statistical model in their original
form. This procedure implicitly assumes that the effect on the risk
of death is log-linear, i.e. that the log relative risk increases or
decreases linearly as the value of a factor increases. Obviously,
this assumption may be wrong for some continuous factors, and
mis-specification of the functional form may lead to wrong
conclusions.
One common strategy to circumvent the assumption of a linear
effect is to convert the continuous predictor into categorical factors
by grouping patients into two or more groups. This enables
researchers to avoid strong assumptions about the relation between
the factor and risk, but at the expense of throwing away informa-
tion. The information loss is greatest with only two groups, but the
approach is widely used, e.g. for factors such as oestrogen and
progesterone receptor (negative vs positive) or S phase fraction
(low vs high). For S phase fraction, for instance, many different
cutpoints are used; Altman et al (1994) listed 19 found in the liter-
ature and several methods for defining the cutpoint. It is often
unclear which cutpoints to use. Sometimes patients are divided
into two groups at the median value, but there is no a priori reason
to assume that half of the patients are at higher risk (Simon and
Altman, 1994). Often the cutpoint is used that gives the best sepa-
ration of the patients into groups with different prognosis by
repeating the analysis with all possible cutpoints. However the P-
value of the test using the ‘best’ cutpoint is invalid without an
Modelling the effects of standard prognostic factors in
node-positive breast cancer
W Sauerbrei1, P Royston2, H Bojar3, C Schmoor1, M Schumacher1 and the German Breast Cancer Study
Group (GBSG)
1Institute of Medical Biometry and Medical Informatics, University of Freiburg, Stefan-Meier-Strasse 26, D-79104, Germany; 2Department of Medical Statistics
and Evaluation, Imperial College School of Medicine, Hammersmith Hospital, Ducane Road, London W12 0NN, UK; 3Department of Chemical Oncology,
University of Düsseldorf, Germany
Summary Prognostic models that predict the clinical course of a breast cancer patient are important in oncology. We propose an approach to
constructing such models based on fractional polynomials in which useful transformations of the continuous factors are determined. The idea
may be applied with all types of regression model, including Cox regression, the method of choice for survival-time data. We analyse a
prospective study of node-positive breast cancer. Seven standard prognostic factors – age, menopausal status, tumour size, tumour grade,
number of positive lymph nodes, progesterone and oestrogen receptor concentrations – were investigated in 686 patients, of whom 299 had
an event for recurrence-free survival and 171 died. We determine a final model with transformations of prognostic factors and compare it with
the more traditional approaches using categorized variables or assuming a straight line relationship. We conclude that analysis using
fractional polynomials can extract important prognostic information which the traditional approaches may miss.
Keywords: breast cancer; prognostic factors; regression modelling; variable transformation; fractional polynomials
1752
British Journal of Cancer (1999) 79(11/12), 1752–1760
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0279
Received 12 January 1998
Revised 11 August 1998
Accepted 20 August 1998
Correspondence to: W SauerbreiModelling prognostic factors in breast cancer 1753
British Journal of Cancer (1999) 79(11/12), 1752–1760 © Cancer Research Campaign 1999
appropriate adjustment for the other tests, and the estimated effect
of the factor is biased (Altman et al, 1994).
Tumour size is often analysed using three categories (≤ 20 mm,
21–50 mm, > 50 mm). For the most important factor, the number
of involved lymph nodes, the categories 0, 1–3, 4–9 and ten or
more are used. The effect of age is investigated in many different
ways: sometimes just as a binary variable comparing young vs old,
where many different cutpoints are in use, or with three categories
or using 5- or 10-year intervals. Based on these categorized data,
estimates of survival rates are compared in a univariate way, or
multivariable models are developed using binary variables to
represent the different categories. The serious problems with
univariate analyses of prognostic factors are well known. The
multivariable approach may lead to simple and interpretable
models, but the loss of power because of categorization (Palta and
Amini, 1985; Lagakos, 1988; Schmoor and Schumacher, 1997)
may result in the analyst failing to notice an important factor. For a
continuous variable the functional relationship with the risk of
death is represented as a step-function, which can give only a
rough idea about the true relationship; it is unlikely that the risk
suddenly changes as one crosses a cutpoint.
In this paper we use a different approach for the analysis of the
effect of continuous factors. It is based on fractional polynomials
(FP) and was recently proposed to investigate the functional form
of the effect of continuous factors in a systematic way (Royston
and Altman, 1994; Sauerbrei and Royston, 1998). The new proce-
dure is a flexible tool making use of the full information available
in the data. It does not assume a linear relationship. Instead, for
each factor the functional effect on the risk of death is assessed
from the data by systematically investigating a set of transforma-
tions which is simple, but nevertheless very flexible, and repre-
sents a wide range of functional forms.
The results of the FP approach and of the traditional approach
based on categorized covariates are compared in investigating the
functional influence of seven standard prognostic factors in a
prospective study on node-positive breast cancer patients of the
German Breast Cancer Study Group (Schumacher et al, 1994). It
will be shown that the FP approach can provide clearer insight into
the nature of the relationship between the values of the factors and
the risk of a new event than usual approaches. This is particularly
so in our study for the effect of the patients’ age.
MATERIALS AND METHODS
The principal eligibility criterion was a histologically verified
primary breast cancer of stage T1a-3aN+M0. Primary local treat-
ment was by a modified radical mastectomy (Patey) with en bloc
axillary dissection with at least six identifiable lymph nodes.
Patients should not be older than 65 years of age and should
present with a Karnofsky index of at least 60. The study was
designed as a Comprehensive Cohort Study (CCS), i.e. patients
who satisfy the entry criteria are informed about the study and are
asked whether they agree to be randomized (Schmoor et al, 1996).
If so, they are randomized to a treatment, otherwise, they or their
physicians choose their preferred treatment. Randomized and
non-randomized patients were included in the present analysis of
prognostic factors.
The study has a 2 ´ 2 factorial design with the four adjuvant
treatment arms: (A) 3 ´ CMF; (B) 3 ´ CMF + TAM; (C) 6 ´ CMF;
and (D) 6 ´ CMF + TAM. Although we could randomize shortly
after the operation, we aimed to randomize as late as possible,
presumably after basic chemotherapy of three cycles, to increase
compliance. Following the statements of the National Cancer
Institute consensus conference, the protocol was modified in
December 1986 with premenopausal patients only randomized
between treatment arms A and C (Consensus Conference, 1985).
Chemotherapy was administered using the modified Bonnadonna
CMF scheme consisting of 500 mg m–2 cyclophosphamide,
40 mg m–2 methotrexate and 600 mg m–2 fluorouracil i.v. on day 1
and 8 of a 4-week treatment period. Hormonal treatment consisted
of a daily dose of 3 ´ 10 mg tamoxifen p.o. over 2 years starting
after the third cycle of CMF. Major prognostic factors evaluated in
the trial were patient’s age, menopausal status, tumour size,
oestrogen and progesterone receptor status, tumour grading
according to Bloom and Richardson, histological tumour type and
number of involved lymph nodes. Histopathologic classification
was re-examined, and grading was performed centrally by one
pathologist for all cases. Hormone receptor content, both ER and
PR, was measured biochemically by a dextran-coated charcoal
method and classified as positive if the respective value was equal
or greater than 20 fmol mg–1. Quality control for the hormone
receptor analysis was performed centrally. Patients were followed
up at regular intervals to ensure detection of any kind of recurrence
at the earliest time possible. For more details of the study see
Schumacher et al (1994).
The primary end point was tumour recurrence or death of a
patient. RFS was defined as time from mastectomy to the first
occurrence of either locoregional or distant recurrence, contra-
lateral tumour, secondary tumour or death; overall survival (OS)
as time from operation to death. Recurrence-free and overall
survival rates were estimated by the Kaplan–Meier product limit
method. The Cox proportional hazards model was used to investi-
gate simultaneously the influence of several factors on the survival
times (Byar, 1984). The risk function for a patient with values (Z1,
Z2, …, Zk) of the prognostic factors can be written as
l0(t) exp(b1Z1 +b2Z2+ … +b kZk)
Table 1 Patient characteristics with respect to prognostic factors. Values in
parentheses are the 25th, 50th (median) and 75th centiles of the data for the
variable in question
Variable Category No. %
Age, years ≤ 45 153 22.3
(46, 53, 61) 46–60 345 50.3
> 60 188 27.4
Menopausal state pre 290 42.3
post 396 57.7
Tumour size, mm ≤ 20 180 26.2
(20,25,35) 21–30 287 41.8
> 30 219 31.9
Tumour grading I 81 11.8
II 444 64.7
III 161 23.5
No. of involved nodes 1–3 376 54.8
(1, 3, 7) 4–9 207 30.2
³ 10 103 15.0
Progesterone receptor, < 20 269 39.2
fmol (7,33,132) ³ 20 417 60.8
Oestrogen receptor, fmol < 20 262 38.2
(8,36,115) ³ 20 424 61.81754 W Sauerbrei et al
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where l0(t) is an unspecified baseline hazard function. The coeffi-
cients b1, b2, …, bk, which are estimated from the data, represent
the influence of the different factors. To investigate the effect of
different prognostic subgroups the variables are defined as indica-
tors for the respective subgroup. The relative risk of the subgroup
defined by Zi in relation to the reference group is then given by
exp(bi). All analyses investigating the influence of prognostic
factors are adjusted for hormonal treatment, whereas the duration
of CMF was not included in the model. All P-values are based on
the likelihood ratio test. To develop a more parsimonious model,
including only variables with an influence on the outcome, we
used backward elimination (selection level 0.05). To investigate
the functional relationship of a continuous factor on RFS and OS,
we used two usual approaches (a) and (b), and a new approach (c):
a. The factor was included in the model as originally measured,
i.e. a log linear relationship between the factor and the risk of
death is assumed. This will be called the ‘linear approach’.
b. The factor was categorized into two or three groups according
to the predefined cutpoints used in the primary analysis of the
randomized part of the trial (Schumacher et al, 1994), i.e. a
step functional relationship between the factor and the risk of
death is assumed. This will be called the ‘step approach’.
c. The recent fractional polynomials approach was used, where
among a defined class of transformations and under some
constraints concerning model complexity the best fitting func-
tional form is selected (Royston and Altman, 1994). For details
see the Appendix. This will be called the ‘FP approach’.
Sauerbrei and Royston (1999) proposed modifications of the
multivariable FP version to incorporate basic medical knowledge
of the types of relationship to be expected between certain predic-
tors and risk. For one variable only, the number of positive lymph
nodes, they decided that the relationship should be modelled as a
function which always increased but which levelled off at a high
number of positive nodes (technically known as a monotonic func-
tion with an asymptote). We adopted the same approach and used
the same simple primary transformation as Sauerbrei and Royston
(1999), namely exp(–0.12 ´ nodes). The factor –0.12 was esti-
mated from the data.
We start with a univariate analysis of the prognostic factors. We
then investigate their influence simultaneously in multivariable
models.
For checking the FP functional form we use generalized addi-
tive models (GAMs; Hastie and Tibshirani, 1990). For a brief
description of this flexible approach see the Appendix. For the
three approaches (a), (b) and (c) the estimated relative risks are
standardized in the sense that the baseline category from the step
approach is taken as a reference with a relative risk of 1.
RESULTS
From July 1984 to December 1989, 41 centres recruited 720
patients, of whom about two-thirds were randomized. Complete
data of the seven standard factors as given in Table 1 were avail-
able for 686 (95.3%) patients, who are taken as the basic patient
population in this paper. After a median follow-up time of nearly 5
years, 299 events for RFS and 171 deaths were observed. Because
of the patients’ preference in the non-randomized part, and
because of the change in protocol concerning premenopausal
patients, only about a third of the patients received hormonal treat-
ment. Age and menopausal status had a strong influence on
whether this therapy was administered. As stated earlier we adjust
all analyses for hormonal treatment.
Univariate models for RFS
In Table 2 we give the results of investigating the functional influ-
ence of the five continuous prognostic factors in univariate
models, adjusted only for hormonal treatment. We list the P-values
for two model comparisons:
a. a linear effect versus no effect
b. the effect of a second degree fractional polynomial versus a
linear effect.
Comparison (a) represents the simplest approach for modelling
a continuous predictor without grouping the values. The first
column of Table 2 shows the strong influence of tumour size,
number of involved lymph nodes and PR, but age and ER seem not
to be prognostic. Comparison (b) is part of our strategy to detect
and model non-linear relationships. By contrast with (a), for age
and ER there are highly significant (P < 0.001) differences
between the second degree FP and the linear model, showing that
these factors have a strong non-linear effect on RES. The influence
of PR is also seen to be non-linear. The effect of exp(–0.12*nodes)
is linear. Since the improvement in fit due to the exponential trans-
formation of nodes compared with a linear model is highly signifi-
cant (Sauerbrei and Royston, 1999), the effect of nodes is also
found to be strongly non-linear. With the step approach, only age is
not significant; the four other continuous variables are significant
at the 1% level. Among the categorical variables, tumour grade
shows a strong effect whereas the effect of menopausal status is
non-significant.
Table 2 P-values for univariate FP analyses of continuous covariates, all adjusted for hormonal treatment
Recurrence-free survival (RFS) Overall survival (OS)
Linear vs none FP (2) vs linear Linear vs none FP (2) vs linear
Age 0.93 < 0.001 0.56 0.75
Tumour size < 0.001 0.23 <0.001 0.62
Transformed nodesa <0.001 0.23 <0.001 0.77
Progesterone receptor <0.001 <0.001 <0.001 <0.001
Oestrogen receptor 0.063 <0.001 0.023 <0.001
aPrimary transformation exp(–0.12 ´ nodes), see end of Section 2 and Appendix.Modelling prognostic factors in breast cancer 1755
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Multivariable models for RFS
In Table 3 we give the final multivariable models for recurrence-
free survival. With the usual approaches based on a linear function
or on categorized variables and with backward elimination as the
selection procedure, grade, PR and number of positive lymph
nodes show a prognostic effect. In Figure 1 we present the esti-
mated relative risk of the lymph nodes component from the final
models. The increase in relative risk can be seen. Patients with at
least ten nodes have a significantly worse prognosis than those
with 4–9 nodes. The linear model may underestimate the effect for
a small number of nodes, whereas it may substantially over-
estimate it for a very large number.
As well as the three factors selected with the linear and step
approaches, the final model based on fractional polynomials indi-
cates a strong effect of age on RFS. Interpretation of the parameter
estimates can best be demonstrated graphically. In Figure 1 it is
shown that the FP approach for nodes implies an increased relative
risk with an asymptote of about a fivefold risk for a large number
of positive nodes. The function fitted by the step approach can be
seen as a reasonable approximation.
In Figure 2 we give the estimated functional relationships for
the age effect which demonstrates that the linear approach does not
show any effect. This could be expected, as age was not significant
in the multivariable model and was only added to the final model
to estimate its effect. The FP approach indicates that younger
patients, up to an age of about 40, have a highly increased risk, and
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Figure 1 Postulated functional influence of the number of positive lymph
nodes (PN) on the log relative risk of recurrence-free survival in multivariable
models according to three modelling approaches. To enable comparison
between models, each of the fitted curves has been standardized
by subtracting an appropriate constant. The functions plotted are
(A) 0.054 ´ PN – 0.0925; (B) step function with log relative risks 0, 0.731,
1.301; (C) –1.9812 ´ exp(–0.12 ´ PN) + 1.6203. (––) Linear function; (- - -)
step function, (– – –) fractional polynomials
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Figure 2 Postulated functional influence of age on the log relative risk of
recurrence-free survival (details as for Figure 1). The functions plotted are
(A) 0.000383´age –0.0151; (B) step function with log relative risks 0, –0.24,
–0.13; (C) 1.7422 ´ (age/50)–2 – 7.8179 ´ (age/50)–0.5 + 5.884. (— —) Linear
function, (- - -) step function, (– – –) fractional polynomials
Figure 3 Postulated functional influence of progesterone receptor (PR) on
the log relative risk of recurrence-free survival (details as for Figure 1). The
functions plotted are (A) –0.0023 ´ PR+0.0125; (B) step function with log
relative risks 0, –0.639; (C) –0.0582 ´ (PR+1)0.5 + 0.131. (— —) Linear
function, (---) step function, (– – –) fractional polynomials
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Table 3 Final multivariable models for recurrence-free survival, adjusted for
hormonal treatment (P-values from likelihood ratio tests)
a) Linear approach
Variables b SE P-value
Grade
10 – –
2 or 3 0.687 0.247 0.002
No. of nodes 0.054 0.007 <0.001
Progesterone receptor (PR) –0.0023 0.0006 <0.001
b) Step approach
Variable with categories  b SE P-value
Grade
10 – –
2 or 3 0.547 0.250 0.019
No. of nodes
1–3 0 – –
4–9 0.731 0.134 <0.001
³ 10 1.301 0.153 <0.001
Progesterone receptor (PR)
< 20 0 – –
³ 20 –0.639 0.120 <0.001
c) FP approach
Variable with transformation  b SE P-value
(age/50)–2 1.742 0.330 <0.001
(age/50)–0.5 –7.818 1.749 <0.001
Grade
10 – –
2 or 3 0.517 0.249 0.026
Transformed nodesa –1.981 0.227 <0.001
Transformed –0.0582 0.0111 <0.001
progesterone receptorb
aPrimary transformation exp(–0.12 * nodes), see end of section 2 and
Appendix. b(PR + 1)0.5.1756 W Sauerbrei et al
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that after a fairly constant period between 40 and 55 years the risk
increases again. In the step approach we added the non-significant
age effect to the corresponding final model in order to demonstrate
the behaviour of this procedure. The effect is very small, perhaps
as a result of choosing the predefined cutpoint of 45 years for the
young age group.
In Figure 3 we show the estimated functional relationships for
PR from the three modelling approaches. In contrast to the linear
approach, the FP approach shows a steep decrease for very small
values.
The effect of grade is similar in the different models with a
better prognosis for grade 1 patients and no differentiation
between grade 2 and grade 3. To check the suggested functional
form of the final model, in Figure 4 we plot the FP function and the
fitted GAM curve with pointwise 95% confidence limits for all
three continuous factors. The GAM curve was fitted for one vari-
able, with the other variables and corresponding FP functions
fixed as given in the final model for RFS.
In each case the confidence limits for the GAM curve include
the fitted FP curve, which suggests that the two models are statisti-
cally compatible. This provides reassurance that the FP approach
has not missed some important feature of the relationship.
Models for OS
In univariate analyses of OS, age has no apparent effect but the
four other continuous variables are all significant (Table 2). The
effect seems to be linear for tumour size only. In multivariable
analysis with the FP approach, only the number of nodes and PR
entered the final model, whose prognostic index is given by
–2.176 ´ exp(–0.12 ´ nodes) – 0.127 ´ (progesterone + 1)0.5.
The graphs for these two factors show that the functions
resemble those for RFS and are supported by the model-checking
method using GAMs (data not shown). With the step approach,
tumour size was also included in the model and had a weak effect.
With the linear approach, tumour size and grade were included in
the model in addition to the two dominating factors (number of
nodes, progesterone receptor).
DISCUSSION
Prognostic factors play an important role in the management of
breast cancer and in clinical research. The role of several standard
factors has been investigated in hundreds of papers and is still the
subject of controversy. Some of the important reasons for the
situation concern statistical aspects such as small sample size or
inadequate ways of modelling complex multivariable relationship
(Simon and Altman, 1994).
Categorization of continuous variables is often used and
certainly has several advantages, including simplicity of the final
model and robustness to outliers or to problems of data quality. Not
least, the analysis is cost-effective in terms of the time, effort and
skill required to undertake it. If several categories are considered in
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Figure 4 Check of the postulated FP functions for recurrence-free survival from the final model using generalized additive models (GAM). –––, FP; - - -, GAM
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the analysis, a test for trend may be used to assess a monotonic
effect of a factor. However, there are several well-known draw-
backs. The final model is a risk step-function which changes
suddenly as one crosses a cutpoint. Because cutpoints are usually
not ‘naturally’ given, and because there is often no consensus as to
a sensible cutpoint, investigators may be tempted to search for the
‘optimal’ cutpoint in their study, ‘optimal’ meaning ‘most signifi-
cant’. The severe problems of this approach are a substantial over-
estimation of the effect size, too small P-values, and loss of
information because of categorization as demonstrated by Altman
et al (1994). Such an approach will lead to different cutpoints in the
single studies, which makes comparing the results of several
studies nearly impossible. Even if the cutpoints are given a priori,
considerable information may be lost. A further problem is terminal
digit preference, which is common with certain measurements (e.g.
tumour size 10, 20 mm). Defining a group as ‘smaller than x’ rather
than ‘smaller than or equal to x’ may give substantially different
results. The effect of terminal digits is much less pronounced if the
data are not categorized. Using the data in continuous form as orig-
inally measured, a straight line is the most common assumption
used to describe the functional influence of a prognostic factor on
the outcome. If the assumption is wrong, there are serious conse-
quences for the inclusion of a prognostic factor in the final model.
In accordance with the literature, the number of positive lymph
nodes is the factor with the strongest influence on the two survival
criteria. With all types of analyses the significant effect can be
demonstrated, but Figure 1 shows the differences. The step-func-
tion model jumps at the predefined cutpoints 3 and 10, but can be
seen as a rough approximation to the form from the final FP
model. The linear model may underestimate the effect for a small
number of nodes, whereas it overestimates this effect for a very
large number, e.g. 40 or more. Based on current medical knowl-
edge we forced the functional influence of the number of nodes to
be monotonic with an asymptote, which we achieved using an
initial exponential transformation (for details see Sauerbrei and
Royston, 1998).
Furthermore, PR is included in all final models for RFS and OS
with a highly significant reduced risk for increasing concentration
whereas ER never showed an effect in the multivariable context.
This result confirms the earlier result in a subpopulation of the
patients analysed here (Schumacher et al, 1994). The FP function
shows a steep decrease for very small values; such a function may
explain the chosen cutpoints (usually between 5 fmol mg–1 and
20 fmol mg–1) to define receptor negativity for the investigation of
the prognostic value of receptor measurements as a binary variable.
For recurrence-free survival tumour grade is also included in the
final models of all three types of analysis. Grades 2 and 3 are
always indicating little or no difference between them, but patients
with that grade 1 tumour have a substantially reduced risk.
Combining grade 2 and 3 is in agreement with results from
Cummings et al (1995) and Pichon et al (1996), who found large
differences between grade 1 and 2 in a model adjusting for axillary
node status, tumour size, age and ER, whereas the risk increased
only slightly from grade 2 to grade 3. Grade was also established
as one of the three factors in the Nottingham Prognostic Index
(Galea, 1992), which seems to be the only prognostic classifica-
tion scheme capable of being validated more than once (Brown et
al, 1993, Balslev et al, 1994, Sauerbrei et al, 1997). Generally, the
issues of which grading schemes to use and the importance or
otherwise of grade as a prognostic factor in a multivariable context
are controversial (Elston and Ellis, 1991; Schumacher et al, 1993).
For overall survival the importance of grade could not be demon-
strated. Grade only entered the final model with the linear
approach, but with categories 1 and 2 combined. This model
was the only one which indicated a strong effect of tumour size
(P < 0.01). Tumour size also entered (P = 0.04) the final model
for OS in the analysis based on categorized variables.
The FP approach clearly demonstrates a strong non-linear effect
of age on RFS. As Figure 2 shows there seems to be a steep
increase in the hazard for patients younger than 40 years. The
model implies that the risk is similar for patients between 40 and
60 years. Age is an independent prognostic factor in addition to the
number of positive lymph nodes, tumour grade and PR, which
contrasts with the conclusions of Kollias et al (1997) who investi-
gated the effect of age in different subgroups defined by the
Nottingham Prognostic Index. Besides the standard factors inves-
tigated here, there seem to be other factors that make breast carci-
nomas in young women different and that may be responsible for
Table 4 Fractional polynomial models for the effect of age on recurrence-free survival. The best-fitting first and second degree models are indicated by
underlining
Fractional polynomials
First-degree Second-degree
Power Model Powers Model Powers Model Powers Model
p c2 pq c2 pq c2 pq c2
–2 6.41 –2 –2 17.09 –1 1 15.56 0 2 11.45
–1 3.39 –2 –1 17.57 –1 2 13.99 0 3 9.61
–0.5 2.32 –2 –0.5 17.61 –1 3 12.37 0.5 0.5 13.37
0 1.53 –2 0 17.52 –0.5 –0.5 16.82 0.5 1 12.29
0.5 0.97 –2 0.5 17.30 –0.5 0 16.18 0.5 2 10.19
1 0.58 –2 1 16.97 –0.5 0.5 15.41 0.5 3 8.32
2 0.17 –2 2 16.04 –0.5 1 14.55 1 1 11.14
3 0.03 –2 3 14.91 –0.5 2 12.74 1 2 8.99
–1 –1 17.58 –0.5 3 10.98 1 3 7.15
–1 –0.5 17.30 0 0 15.36 2 2 6.87
–1 0 16.85 0 0.5 14.43 2 3 5.17
–1 0.5 16.25 0 1 13.44 3 3 3.67
See Appendix for further details.1758 W Sauerbrei et al
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the bad prognosis (Walker et al, 1996). With the two usual analysis
approaches we could not demonstrate an effect of age on RFS.
This is not surprising for the linear approach because the effect
seems to be strongly non-linear. With the step approach we could
not establish the age effect because we used the categories based
on predefined cutpoints of 45 and 60 years (Schumacher et al,
1994). This decision was intended to avoid well-known problems
with the optimal cutpoints approach (Altman et al, 1994). Our esti-
mated FP function seems to explain the current discussion about
several cutpoints for young age which range at least from 33
(Rochefordiere et al, 1993) to 45 (Crowe et al, 1994; Collett et al,
1996). Moreover, our results give some indication that the effect of
age is sometimes not established because of differences in statis-
tical approaches. Besides the three different types of postulated
functions, the other factors studied may have a strong influence on
the final conclusions on the age effect as an independent prog-
nostic factor in a multivariable context. Because of the large varia-
tion in competing factors between different studies a final
conclusion cannot be reached at present. As an example, Chung et
al (1996) concluded that ‘women 40 years of age and younger
have a worse 5 year cancer-specific survival than their older coun-
terparts’. They included 3722 women in their study, used age in
10-year intervals and analysed the data in three groups by stage. In
a study on 2879 women, Kollias et al (1997) compared patients
aged < 35 years with older age groups, stratified by three groups
defined by the Nottingham Prognostic Index, and concluded that
‘age itself had no influence on the prognosis of the individual’.
Pichon et al (1996) had complete data for 1665 patients on the
covariates grade, number of axillary nodes, tumour size, ER status,
TNM stage, menopausal status and age. For disease-free and
metastasis-free survival they found a strong age effect (relative
risk 2.8) in a multivariable model by comparing patients ≤ 35 years
with those older than 35. However, as with our analysis, age did
not enter the final model for overall survival.
An important step for an improvement in summarizing informa-
tion from prognostic factors would be a widely accepted standard
prognostic model. We see the Nottingham Prognostic Index as the
most often validated and accepted classification scheme. As
recently published for node-negative patients where, in addition to
changes to the weights of the component of the NPI, in one of our
proposals only age was added to the NPI (Sauerbrei et al, 1997),
we see the results from the NPI and our proposals as a starting
point for an urgently needed accepted and sensible description of
the influence of standard factors.
FPs may also be used to investigate a possible treatment/
covariate interaction. After fitting a single model with a separate
FP curve for each treatment group, and with the rest of the multi-
variable model unchanged, a substantial difference in the type of
FP curve for each group may indicate of a treatment/covariate
interaction. Alternatively, the original FP transformation, such as
square root, may be retained and a separate slope estimated for the
transformed variable in each group. A significant difference in
the slopes may be evidence of an interaction. However, some
methodological issues connected with this way of analysing treat-
ment/covariate interactions are unresolved.
We have proposed a multivariable approach to analysis which
avoids categorization and retains continuous variables as contin-
uous. This avoids loss of information and postulates functional
forms that are more realistic than step functions. If grouping is
required for clinical reasons, e.g. to define criteria for risk adapted
trials, it can be done in the usual way, but based on a more sensible
prognostic index suggested by the shape of the FP curve. Given the
FP model, we checked the proposed form for each continuous vari-
able against that from generalized additive models. Because the
final model of a GAM approach cannot be given as a concise
mathematical expression, this alternative makes clinical interpreta-
tion and application very difficult. However, it can be seen as an
advantageous approach to demonstrate that the proposed FP func-
tion does exhibit essentially all the important information present
in the data. Of course, any postulated models have to be validated
in new studies.
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APPENDIX
Fractional polynomials
Suppose we wish to construct a Cox proportional-hazards regres-
sion model with which to predict the relative risk of disease recur-
rence in terms of age (the patient’s age, regarded as a continuous
variable). A possible non-linear function with which to represent
the relationship is a quadratic polynomial model in age, as
follows:
log RR = a + b ´ age1 + c ´ age2
Quadratic polynomials, while undoubtedly useful, suffer various
disadvantages as regression models, including a limited range of
possible curve shapes. Generalizations of polynomials known as
fractional polynomials (Royston and Altman, 1994) are obtained
by replacing the whole-number powers 1 and 2 by less restrictive
numbers, p and q:
log RR = a + b ´ agep + c ´ ageq
The powers p and q are not allowed to be completely free, but are
chosen from the small set –2, –1, –0.5, 0, 0.5, 1, 2, 3. The ‘power’
0 represents a natural logarithmic transformation, so that age0 is
defined as loge(age). This simple extension generates a consider-
able range of new curve shapes which are useful in data analysis
(Royston and Altman, 1994). For example, a fractional polyno-
mial with powers (0, 2), that is with p = 0 and q = 2, is
a + b ´ log(age) + c ´ age2
When p = q, the complete family of curves also includes functions
of the form
log RR = a + b ´ agep + c ´ agep ´ log(age).
These are known as ‘repeated powers models’ because they repre-
sent the mathematical limit attained when p and q approach each
other arbitrarily closely.
First-degree fractional polynomials are simple, familiar power
transformations of the predictor. They include reciprocal, loga-
rithmic, square root and square transformations. They are guaran-
teed to produce fitted curves that are ‘monotonic’, that is, that
always increase or always decrease as the predictor increases.
Second-degree fractional polynomial curves have at most one
turning point (minimum or maximum) which may or may not lie
within the observed range of predictor values. However, some
second-degree curves are monotonic, and it is straightforward to
determine this by inspecting the signs of the powers p, q and the
coefficients b, c.
Higher degree fractional polynomials have greater flexibility
still, but we do not generally recommend their use in data analysis
and did not use them in the analyses in the present paper.
We now consider fractional polynomial model selection. A frac-
tional polynomial of first-degree is of the form a+b agep. The
special case p = 1 corresponds to a straight line is our preferred
choice unless there is convincing evidence that it does not fit the
data adequately. We adopt a forward selection approach to look for
such evidence. For a given data-set, we fit the eight regression
models a + b x with x = age–2, x = age–1, …, x = age3 in turn and
find the value of p which maximizes the likelihood. This is equiv-
alent to maximizing the model c2 statistic or to minimizing the
deviance, which is defined as minus twice the log likelihood. The
hypothesis that p = 1 is tested against p ¹1 using a c2 test with one
degree of freedom (df). If the test is significant at the 5% level, the
linear model is rejected. Next we look for evidence of a more
complex curve shape by finding the best-fitting second-degree
fractional polynomial. This involves searching for the powers p
and  q which maximize the model c2 among the 36 two-term
models of the form a + b agep + c ageq and a + b agep + c agep
log(age). The required hypothesis test of second-degree versus
first-degree fractional polynomial now has 2 df, one for estimating
the regression coefficient c and one for estimating the power q.
With no prior knowledge about the shape of the relationship we
again perform the test at the 5% significance level. If we want to
force the relation to be monotonic, for example because of prior
medical knowledge, we prefer a first-degree fractional polynomial
unless there is strong contrary evidence. We may therefore test at a
more rigorous significance level such as 1% to reduce the risk of
choosing an inappropriate model.
To illustrate the process, Table 4 gives the results of fitting frac-
tional polynomials with age as the only predictor of recurrence-
free survival. The c2 value for a straight line model is 0.58 (see p =
1 in Table 4), which gives no indication of a linear prognostic
effect of age (P = 0.4). However, the best-fitting first degree frac-
tional polynomial has power p = –2 and a model c2 of 6.41, indi-
cating a significant non-linear effect (deviance difference = 5.83
on 1 df, P = 0.02). The best second-degree fractional polynomial
has powers p = –2, q = –0.5 and a model c2 of 17.61. The fit is
convincingly better than that of the first-degree model (deviance
difference = 11.20 on 2 df, P = 0.004). Note that several second-
degree models have c2 values not much smaller than that of the
best model. This is a typical feature of such an analysis and is
similar to deciding in favour of the best model in all-subsets vari-
able selection. It implies some arbitrariness in the final model. For
example, there are seven models with c2 > 17, but their fitted
curves turn out to be much alike.
When the model may contain several continuous predictors (the
usual situation with prognostic factor studies), it is impracticable
to search for the best model among all possible combinations of
powers for each of the predictors. Instead we use a procedure
based on backward elimination of uninfluential variables and
selection of the best fractional polynomial for each predictor in
turn, adjusting for the other predictors. Details are given by
Sauerbrei and Royston (1999).
Generalized additive models
Generalized additive models or GAMs (Hastie and Tibshirani,
1990) provide a flexible approach to modelling curved regression
relationships. The conventional multiple linear regression function1760 W Sauerbrei et al
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b1Z1 +  b2Z2+ … + bkZk is replaced with a sum of functions,
f(Z1) + f(Z2) + … + f(Zk). Each ‘f’ is a cubic smoothing spline
(a special type of cubic polynomial) whose complexity is deter-
mined by its ‘equivalent degrees of freedom’ or edf. A higher edf
gives a more flexible family of curve shapes. Rather than fit a
GAM for all the prognostic factors simultaneously we compared a
GAM (5 edf) with the FP for each predictor individually, keeping
the rest of the original FP model. The fitted GAM curves and
pointwise 95% confidence limits (as a guide to the precision of the
curve) were plotted for each predictor.